Analysts Issue Forecasts for Editas Medicine Q2 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Research analysts at Zacks Research increased their Q2 2026 earnings per share estimates for shares of Editas Medicine in a research report issued to clients and investors on Tuesday, May 26th. Zacks Research analyst Team now expects that the company will post earnings of ($0.32) per share for the quarter, up from their previous forecast of ($0.34). The consensus estimate for Editas Medicine’s current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Editas Medicine’s Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.25) EPS, Q1 2027 earnings at ($0.34) EPS, FY2027 earnings at ($1.35) EPS, Q1 2028 earnings at ($0.36) EPS and FY2028 earnings at ($1.37) EPS.

Several other brokerages have also commented on EDIT. JonesTrading raised Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Tuesday, March 10th. Wall Street Zen lowered Editas Medicine from a “hold” rating to a “sell” rating in a research note on Sunday, May 10th. Robert W. Baird set a $6.00 price objective on Editas Medicine in a research note on Monday, March 9th. Chardan Capital boosted their price objective on Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a research note on Monday, April 20th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.40.

Editas Medicine Price Performance

Shares of EDIT stock opened at $3.57 on Thursday. The stock’s fifty day simple moving average is $2.83 and its 200 day simple moving average is $2.43. The firm has a market cap of $349.54 million, a price-to-earnings ratio of -2.90 and a beta of 2.14. Editas Medicine has a one year low of $1.60 and a one year high of $4.54.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $6.37 million. Editas Medicine had a negative return on equity of 677.39% and a negative net margin of 281.59%.

Institutional Investors Weigh In On Editas Medicine

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EDIT. Renaissance Technologies LLC increased its holdings in Editas Medicine by 138.0% in the fourth quarter. Renaissance Technologies LLC now owns 3,039,778 shares of the company’s stock valued at $6,232,000 after purchasing an additional 1,762,378 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Editas Medicine by 122.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,430,000 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Editas Medicine by 761.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 800,023 shares of the company’s stock valued at $2,776,000 after purchasing an additional 707,181 shares during the last quarter. Two Sigma Investments LP increased its holdings in Editas Medicine by 63.3% in the third quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company’s stock valued at $5,497,000 after purchasing an additional 614,229 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in Editas Medicine in the fourth quarter valued at about $1,166,000. Institutional investors own 71.90% of the company’s stock.

Editas Medicine News Summary

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Investors showed strong speculative interest, with unusually heavy call buying suggesting some traders are positioning for further upside in Editas Medicine (EDIT).
• Positive Sentiment: HC Wainwright reiterated a bearish earnings outlook but the note did not materially worsen the company’s already negative profit profile, while keeping attention on future pipeline execution rather than near-term earnings.
• Positive Sentiment: Editas reported promising preclinical data for EDIT-401, showing ~90% or greater reductions in LDL-C, Lp(a), and ApoB in non-human primates, which supports the drug’s potential in hyperlipidemia and cardiovascular risk reduction. Article Title
• Positive Sentiment: The company also said it is on track to submit a clinical trial notification by mid-2026 and expects early human proof-of-concept data by year-end, which may reinforce optimism around its lead program. Article Title
• Negative Sentiment: Editas priced an underwritten public offering of more than 55.5 million shares plus warrants, which is pressuring the stock because it increases dilution risk for existing shareholders. Article Title
• Negative Sentiment: The company also suspended and terminated a prior at-the-market offering program, underscoring its ongoing need to raise capital and highlighting financing overhangs. Article Title

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and ?-thalassemia using an ex vivo editing approach.